Wave Life Sciences reports INLIGHT trial Activin E reductions up to 85% for WVE-007

The INLIGHT first-in-human trial of WVE-007 (GalNAc-siRNA targeting INHBE) showed statistically significant, dose-dependent Activin E reductions of up to 85% at Day 29 after a single dose, exceeding preclinical thresholds linked to weight loss and prevention of rebound weight gain. Activin E reduction in the lowest-dose cohort was sustained through six months, supporting once- or twice-yearly dosing. The data validate target engagement and support continued dose escalation and upcoming body-composition readouts.

Key facts

Filed: Nov 10, 2025, 12:35 PM
Event: Topline results
Direction: Positive
Company: WVEWave Life Sciences
Asset: WVE-007
Source: SEC 8-K
Confidence: Sourced
p value: <0.0001
activin e reduction: 85% (Cohort 3), 75% (Cohort 2), 56% (Cohort 1)
activin e sustained: 6 months (Cohort 1)

Source excerpt

EX-99.1 2 d44041dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Wave Life Sciences Reports Third Quarter 2025 Financial Results and Provides Business Update WVE-007, an INHBE GalNAc-siRNA for obesity designed to drive fat loss while preserving muscle mass, achieved dose-dependent, mean reductions of Activin E of up to 85% in INLIGHT clinical trial, exceeding levels that led to weight loss and prevention of rebound weight gain following cessation of GLP-1 in preclinical models Activin E reduction in lowest single dose cohort of INLIGHT was sustained through six months, supporting once or twice a year dosing Achieved key AATD treatment goals to recapitulate the MZ phenotype with WVE-006, GalNAc-RNA editing oligonucleotide, in RestorAATion-2 trial: AAT protein exceeded 20 µM during an acute phase response, basal AAT levels reached 13 µM, wild-type M-AAT protein reached 64% of serum AAT, Z-AAT was reduced by 60% WVE-N531 in DMD and WVE-003 in HD remain on track Cash and cash equivalents of $196.2 million as of September 30, 2025; subsequent to quarter-end, additional $72.1 million in ATM proceeds and committed GSK milestones extend expected cash runway into 2Q 2027 Investor conference call and webcast at 8:30 a.m. ET today CAMBRIDGE, Mass., November 10, 2025 – Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced financial results for the third quarter ended

SEC 8-K